FDA Clears Siemens Mammography System
Siemens Healthcare has received FDA clearance for their MAMMOMAT Inspiration Prime Edition lower dose mammography system.
Siemens Healthcare has received FDA clearance for their MAMMOMAT Inspiration Prime Edition mammography system, which lowers radiation dose by up to 30 percent, the company said.
This latest MAMMOMAT system reduces dose by replacing the standard scatter radiation grid with a new algorithm for progressive image reconstruction, according to Siemens. The algorithm can identify scatter-causing structures and calculating a corrected image. This may enable the complete use of primary radiation to achieve lower dose, the company said.
The design of the MAMMOMAT Inspiration Prime Edition obviates the need for a grid, the company said, and lower doses compared to the predecessor model are needed for high-quality images. This edition is based the MAMMOMAT Inspiration platform which has been used since 2007.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
